CD274 and cancer: Checkpoint inhibitors targeting the programmed cell death-1 (PD-1) receptor on T-cells and the programmed cell death-1 ligand 1 (PD-L1) expressed by cancer cells, shown in Figure 5, are the most common, and patient tumors are often evaluated for overexpression of the PD-L1 marker before deciding whether to employ this treatment.